Cargando…

Ceftazidime resistance in Pseudomonas aeruginosa is multigenic and complex

Pseudomonas aeruginosa causes a wide range of severe infections. Ceftazidime, a cephalosporin, is a key antibiotic for treating infections but a significant proportion of isolates are ceftazidime-resistant. The aim of this research was to identify mutations that contribute to resistance, and to quan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramsay, Kay A., Rehman, Attika, Wardell, Samuel T., Martin, Lois W., Bell, Scott C., Patrick, Wayne M., Winstanley, Craig, Lamont, Iain L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10187892/ https://www.ncbi.nlm.nih.gov/pubmed/37192202 http://dx.doi.org/10.1371/journal.pone.0285856

Ejemplares similares

The Effects of Sub-inhibitory Antibiotic Concentrations on Pseudomonas aeruginosa: Reduced Susceptibility Due to Mutations
por: Ramsay, Kay A., et al.
Publicado: (2021)

Genome evolution drives transcriptomic and phenotypic adaptation in Pseudomonas aeruginosa during 20 years of infection
por: Wardell, Samuel J.T., et al.
Publicado: (2021)

Ceftolozane–tazobactam- and ceftazidime–avibactam-resistant Pseudomonas aeruginosa mastoiditis
por: Jacobs, Jeremy, et al.
Publicado: (2020)

Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by Pseudomonas aeruginosa
por: Daikos, George L., et al.
Publicado: (2021)

Reversion of Ceftazidime Resistance in Pseudomonas aeruginosa under Clinical Setting
por: Liu, Qi, et al.
Publicado: (2022)

2254. Multicenter Evaluation of Ceftazidime–Avibactam for Multidrug-Resistant Pseudomonas aeruginosa Infections
por: Jorgensen, Sarah C J, et al.
Publicado: (2019)

In vivo translational assessment of the GES genotype on the killing profile of ceftazidime, ceftazidime/avibactam and meropenem against Pseudomonas aeruginosa
por: Gill, Christian M, et al.
Publicado: (2022)

Pseudomonas aeruginosa adaptation and diversification in the non-cystic fibrosis bronchiectasis lung
por: Hilliam, Yasmin, et al.
Publicado: (2017)

Proteomic analysis of ceftazidime and meropenem-exposed Pseudomonas aeruginosa ATCC 9027
por: Ngo, Hong Loan, et al.
Publicado: (2023)

Pseudomonas aeruginosa is oxygen-deprived during infection in cystic fibrosis lungs, reducing the effectiveness of antibiotics
por: Martin, Lois W, et al.
Publicado: (2023)

Severe Keratitis Caused by Pseudomonas aeruginosa Successfully Treated with Ceftazidime Associated with Acetazolamide
por: Hue, Benoit, et al.
Publicado: (2009)

In vitro activities of cellulase and ceftazidime, alone and in combination against Pseudomonas aeruginosa biofilms
por: Kamali, Esmat, et al.
Publicado: (2021)

Evolutionary diversification of Pseudomonas aeruginosa in an artificial sputum model
por: Davies, Emily V., et al.
Publicado: (2017)

Activation of a Cell Surface Signaling Pathway in Pseudomonas aeruginosa Requires ClpP Protease and New Sigma Factor Synthesis
por: Bishop, Thomas F., et al.
Publicado: (2017)

Comparison of efficiency of intravitreal ceftazidime and intravitreal cefepime in the treatment of experimental Pseudomonas aeruginosa endophthalmitis
por: Deniz, Nurettin, et al.
Publicado: (2013)

Continuous infusion versus intermittent infusion of ceftazidime for the treatment of pneumonia caused by Pseudomonas aeruginosa
por: Lorente, L, et al.
Publicado: (2005)

Emergence of Ceftazidime- and Avibactam-Resistant Klebsiella pneumoniae Carbapenemase-Producing Pseudomonas aeruginosa in China
por: Zhu, Yiwei, et al.
Publicado: (2021)

Ceftazidime/Avibactam versus Polymyxin B in the Challenge of Carbapenem-Resistant Pseudomonas aeruginosa Infection
por: Chen, Juan, et al.
Publicado: (2022)

Ceftazidime/Avibactam for the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Infection in Lung Transplant Recipients
por: Chen, Juan, et al.
Publicado: (2023)

Ceftazidime-assisted synthesis of ultrasmall chitosan nanoparticles for biofilm penetration and eradication of Pseudomonas aeruginosa
por: Zheng, Xiaoran, et al.
Publicado: (2023)

Pseudomonas aeruginosa Evolutionary Adaptation and Diversification in Cystic Fibrosis Chronic Lung Infections
por: Winstanley, Craig, et al.
Publicado: (2016)

Preparation, characterization and in vitro antimicrobial activity of liposomal ceftazidime and cefepime against Pseudomonas aeruginosa strains
por: Torres, Ieda Maria Sapateiro, et al.
Publicado: (2012)

Evaluation of Ceftazidime/Avibactam Administration in Enterobacteriaceae and Pseudomonas aeruginosa Bloodstream Infections by Monte Carlo Simulation
por: Dai, Yuanyuan, et al.
Publicado: (2021)

Comparison of In Vitro Activity of Ceftazidime-Avibactam and Imipenem-Relebactam against Clinical Isolates of Pseudomonas aeruginosa
por: Wang, Leilei, et al.
Publicado: (2023)

β-lactam Resistance in Pseudomonas aeruginosa: Current Status, Future Prospects
por: Glen, Karl A., et al.
Publicado: (2021)

The PitA protein contributes to colistin susceptibility in Pseudomonas aeruginosa
por: Erdmann, Mareike B., et al.
Publicado: (2023)

2385. Ceftazidime–Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas aeruginosa
por: Papp-Wallace, Krisztina M, et al.
Publicado: (2018)

Aminoglycoside-Modifying Enzymes Are Sufficient to Make Pseudomonas aeruginosa Clinically Resistant to Key Antibiotics
por: Thacharodi, Aswin, et al.
Publicado: (2022)

Whole genome sequencing reveals the emergence of a Pseudomonas aeruginosa shared strain sub-lineage among patients treated within a single cystic fibrosis centre
por: Wee, Bryan A., et al.
Publicado: (2018)

Persistent Bacteremia from Pseudomonas aeruginosa with In Vitro Resistance to the Novel Antibiotics Ceftolozane-Tazobactam and Ceftazidime-Avibactam
por: Gangcuangco, Louie Mar, et al.
Publicado: (2016)

Genomic Analysis of Ceftazidime/Avibactam-Resistant GES-Producing Sequence Type 235 Pseudomonas aeruginosa Isolates
por: Recio, Raúl, et al.
Publicado: (2022)

Molecular Mechanisms of Resistance to Ceftazidime/Avibactam in Clinical Isolates of Enterobacterales and Pseudomonas aeruginosa in Latin American Hospitals
por: Mojica, María Fernanda, et al.
Publicado: (2023)

Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical Pseudomonas aeruginosa isolates from Switzerland
por: Babouee Flury, Baharak, et al.
Publicado: (2023)

Carbapenem-Resistant Pseudomonas aeruginosa Spondylodiscitis Treated with Ceftazidime-Avibactam: A Case Report with Literature Review
por: Danda, Guilherme José da Nóbrega, et al.
Publicado: (2023)

Transmission, adaptation and geographical spread of the Pseudomonas aeruginosa Liverpool epidemic strain
por: Moore, Matthew P., et al.
Publicado: (2021)

Interactions between an anti-sigma protein and two sigma factors that regulate the pyoverdine signaling pathway in Pseudomonas aeruginosa
por: Edgar, Rebecca J, et al.
Publicado: (2014)

Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates
por: Montero, María M., et al.
Publicado: (2021)

Antibiotic perturbation of mixed-strain Pseudomonas aeruginosa infection in patients with cystic fibrosis
por: Tai, Anna S., et al.
Publicado: (2017)

Pseudomonas aeruginosa Exhibits Frequent Recombination, but Only a Limited Association between Genotype and Ecological Setting
por: Kidd, Timothy J., et al.
Publicado: (2012)

Expression of the MexXY-OprM efflux system in Pseudomonas aeruginosa with discordant cefepime/ceftazidime susceptibility profiles
por: Laohavaleeson, Somvadee, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_bpuourj2mii27jfqn34o32hla0